--- title: "Ironwood Pharma | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 106.51 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285537526.md" datetime: "2026-05-07T11:13:43.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285537526.md) - [en](https://longbridge.com/en/news/285537526.md) - [zh-HK](https://longbridge.com/zh-HK/news/285537526.md) --- # Ironwood Pharma | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 106.51 M Revenue: As of FY2026 Q1, the actual value is USD 106.51 M, beating the estimate of USD 92.1 M. EPS: As of FY2026 Q1, the actual value is USD 0.24. EBIT: As of FY2026 Q1, the actual value is USD 80.02 M. #### Total Revenue Ironwood Pharmaceuticals, Inc. reported total revenue of $106.5 million in the first quarter of 2026, a significant increase from $41.1 million in the first quarter of 2025 . This revenue consisted of $104.2 million from the company’s share of net profits from LINZESS sales in the U.S. and $2.3 million in royalties and other revenue for the first quarter of 2026 . In the first quarter of 2025, total revenue comprised $38.8 million from LINZESS U.S. net profits share and $2.3 million in royalties and other revenue . #### Operational Metrics - **LINZESS U.S. Net Sales**: LINZESS U.S. net sales, as reported by AbbVie Inc., were $272.5 million in the first quarter of 2026, a 97% increase compared to $138.5 million in the first quarter of 2025 . This growth was primarily driven by a 5% demand growth and significantly improved net price . - **LINZESS Prescription Demand**: Total LINZESS prescription demand was 56.0 million capsules in the first quarter of 2026, a 5% increase year-over-year compared to the first quarter of 2025 . - **LINZESS Commercial Margin**: The commercial margin for LINZESS was 76% in the first quarter of 2026, an increase from 52% in the first quarter of 2025 . - **Net Profit for LINZESS U.S. Brand Collaboration**: The net profit for the LINZESS U.S. brand collaboration, net of commercial and R&D expenses, was $204.7 million in the first quarter of 2026, representing a 211% increase compared to $65.9 million in the first quarter of 2025 . - **Collaboration Revenue to Ironwood**: Ironwood Pharmaceuticals, Inc. recorded $104.2 million in collaboration revenue related to U.S. LINZESS sales in the first quarter of 2026, a 169% increase from $38.8 million in the first quarter of 2025 . - **Total Costs and Expenses**: Total costs and expenses were $33.9 million in the first quarter of 2026, a decrease from $70.3 million in the first quarter of 2025 . Research and development (R&D) expenses decreased to $21.9 million in the first quarter of 2026 from $27.4 million in the first quarter of 2025 . Selling, general and administrative (SG&A) expenses also decreased to $12.0 million from $24.3 million over the same period . Restructuring expenses were - $40 thousand in the first quarter of 2026, compared to $18.6 million in the first quarter of 2025 . - **Interest Expense**: Interest expense increased to $9.1 million in the first quarter of 2026 from $8.1 million in the first quarter of 2025 . - **Interest and Investment Income**: Interest and investment income rose to $1.7 million in the first quarter of 2026 from $0.9 million in the first quarter of 2025 . - **Income Tax Expense**: Income tax expense was $24.4 million in the first quarter of 2026, up from $1.1 million in the first quarter of 2025 . - **GAAP Net Income (Loss)**: GAAP net income was $40.8 million in the first quarter of 2026, compared to a GAAP net loss of - $37.4 million in the first quarter of 2025 . - **Adjusted EBITDA**: Adjusted EBITDA was $76.7 million in the first quarter of 2026, a significant improvement from - $4.7 million in the first quarter of 2025 . #### Cash Flow - **Cash and Cash Equivalents**: Ironwood Pharmaceuticals, Inc. ended the first quarter of 2026 with $220.5 million in cash and cash equivalents, an increase from $215.5 million at the end of 2025 . - **Cash from Operations**: The company generated $5.1 million in cash from operations in the first quarter of 2026, down from $20.0 million in the first quarter of 2025 . - **Accounts Receivable**: Accounts receivable totaled $105.8 million as of March 31, 2026 . - **Revolving Credit Facility**: The outstanding principal balance on the revolving credit facility was $385.0 million as of March 31, 2026 . #### Outlook / Guidance Ironwood Pharmaceuticals, Inc. maintains its full-year 2026 financial guidance . The company expects U.S. LINZESS Net Sales to be between $1.125 billion and $1.175 billion, driven by improved net price and low-single digit percentage demand growth . Total revenue is projected to be between $450 million and $475 million, with Adjusted EBITDA expected to be greater than $300 million . ### Related Stocks - [IRWD.US](https://longbridge.com/en/quote/IRWD.US.md) ## Related News & Research - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Yext to Announce First Quarter Fiscal Year 2027 Financial Results on June 2, 2026 | YEXT Stock News](https://longbridge.com/en/news/286970613.md) - [GDEV announces results for the first quarter of 2026 | GDEV Stock News](https://longbridge.com/en/news/286909689.md) - [OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026 | OSTX Stock News](https://longbridge.com/en/news/286607728.md)